ORTEXORTEX News
Live short interest, options flow, and signals — free on ORTEX.Sign up free →
Market Commentary

COO Buys, Activist Dumps: Fresh Filings Stand Out

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 1 min read

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

Insider filings reported this week reveal a sharp split between opportunistic buying and large-scale exits.

UBER President and COO Andrew MacDonald filed this week disclosing open-market purchases totalling roughly $5.3M across two tranches on September 4. He bought 54,325 shares plus an additional 15,675 shares at market prices. C-suite purchases of this size — using real cash, not options — carry weight. Uber has drawn growing social media attention in recent weeks around its autonomous vehicle strategy.

At ILMN, activist fund Corvex Management filed disclosing sales of over $34M in Illumina stock across two trades on September 2 and 4. Corvex holds a board seat, making these exits notable. The sales suggest the activist may be trimming a position after years of pressure on the genomics company.

NMIH CEO Adam Pollitzer reported selling $7.7M of NMI Holdings shares on September 4. The filing was entered the same day, suggesting a discretionary rather than pre-planned move — though that detail warrants watching.

Two directors at HELP (Cybin) filed purchases totalling roughly $2.4M combined. The psychedelics biotech has been active on social media. Director-level buying at this scale in a small-cap name is a stronger signal than routine executive grants.

Meanwhile, WBD Director Kenneth Lowe disclosed selling $5.7M of Warner Bros. Discovery shares on September 3.

This is not financial advice.

Stocks in this article

How this article was generated

Generated
15 Sept 2026, 00:20
Prompt version
v1.0
Data sources
Institutional positioning

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.